Assessment of the DNA Mismatch Repair System Is Crucial in Colorectal Cancers Necessitating Adjuvant Treatment: A Propensity Score-Matched and Win Ratio Analysis.

On the contrary, among 157 patients undergoing adjuvant chemotherapy (a heterogeneous group of node-positive and/or pT4 and/or radically resected liver metastases patients; i.e., high-risk stage II patients and stage ≥ III cancers), MSS patients showed significantly better DFS rates (HR = 0.37; 95% CI 0.14–0.89; p = 0.005) and nearly significant OS rates (HR = 0.51; 95% CI 0.20–1.29; p = 0.07) than MSI patients, thus demonstrating that MSI tumors in advanced stages, requiring adjuvant therapy, are significantly disadvantaged or even harmed with conventional chemotherapy schedules ( Figure 2 and Figure 3 ). 3.2.

also in 3,279 other papers